메뉴 건너뛰기




Volumn 8, Issue 8, 2013, Pages

Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; HISTONE H2AX; PANOBINOSTAT;

EID: 84883137069     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074253     Document Type: Article
Times cited : (34)

References (35)
  • 1
    • 20144373530 scopus 로고    scopus 로고
    • Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects
    • 15685244
    • Dearnaley DP, Hall E, Lawrence D, Huddart RA, Eeles R, et al. (2005) Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92: 488-498. PubMed: 15685244.
    • (2005) Br J Cancer , vol.92 , pp. 488-498
    • Dearnaley, D.P.1    Hall, E.2    Lawrence, D.3    Huddart, R.A.4    Eeles, R.5
  • 2
    • 33748096108 scopus 로고    scopus 로고
    • Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer
    • doi: 10.1016/j.juro.2006.06.002
    • Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, et al. (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176: 1415-1419. doi:10.1016/j.juro.2006.06.002. PubMed: 16952647.
    • (2006) J Urol , vol.176 , pp. 1415-1419
    • Zelefsky, M.J.1    Chan, H.2    Hunt, M.3    Yamada, Y.4    Shippy, A.M.5
  • 3
    • 53049089057 scopus 로고    scopus 로고
    • Postradiation sensitization of the histone deacetylase inhibitor valproic acid
    • doi: 10.1158/1078-0432.CCR-08-0643
    • Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, et al. (2008) Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14: 5410-5415. doi:10.1158/1078-0432.CCR-08-0643. PubMed: 18765532.
    • (2008) Clin Cancer Res , vol.14 , pp. 5410-5415
    • Chinnaiyan, P.1    Cerna, D.2    Burgan, W.E.3    Beam, K.4    Williams, E.S.5
  • 4
    • 84874410182 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
    • 23459471
    • Ververis K, Hiong A, Karagiannis TC, Licciardi PV, (2013) Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7: 47-60. PubMed: 23459471.
    • (2013) Biologics , vol.7 , pp. 47-60
    • Ververis, K.1    Hiong, A.2    Karagiannis, T.C.3    Licciardi, P.V.4
  • 5
    • 4143087257 scopus 로고    scopus 로고
    • Histone deacetylase inhibition and estrogen signalling in human breast cancer cells
    • doi: 10.1016/j.bcp.2004.04.031
    • Margueron R, Duong V, Castet A, Cavaillès V, (2004) Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem Pharmacol 68: 1239-1246. doi:10.1016/j.bcp.2004.04.031. PubMed: 15313422.
    • (2004) Biochem Pharmacol , vol.68 , pp. 1239-1246
    • Margueron, R.1    Duong, V.2    Castet, A.3    Cavaillès, V.4
  • 6
    • 67349285731 scopus 로고    scopus 로고
    • Enhancing the apoptotic and therapeutic effects of HDAC inhibitors
    • doi: 10.1016/j.canlet.2009.02.042
    • Frew AJ, Johnstone RW, Bolden JE, (2009) Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 280: 125-133. doi:10.1016/j.canlet.2009.02.042. PubMed: 19359091.
    • (2009) Cancer Lett , vol.280 , pp. 125-133
    • Frew, A.J.1    Johnstone, R.W.2    Bolden, J.E.3
  • 7
    • 69849110970 scopus 로고    scopus 로고
    • Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors
    • doi: 10.2217/fon.09.36
    • Prince HM, Bishton MJ, Johnstone RW, (2009) Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 5: 601-612. doi:10.2217/fon.09.36. PubMed: 19519200.
    • (2009) Future Oncol , vol.5 , pp. 601-612
    • Prince, H.M.1    Bishton, M.J.2    Johnstone, R.W.3
  • 8
    • 31544464120 scopus 로고    scopus 로고
    • Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589
    • doi: 10.1158/1078-0432.CCR-05-1132
    • Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, et al. (2006) Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 12: 634-642. doi:10.1158/1078-0432.CCR-05-1132. PubMed: 16428510.
    • (2006) Clin Cancer Res , vol.12 , pp. 634-642
    • Qian, D.Z.1    Kato, Y.2    Shabbeer, S.3    Wei, Y.4    Verheul, H.M.5
  • 9
    • 77951884767 scopus 로고    scopus 로고
    • A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
    • doi: 10.1007/s00280-010-1289-x
    • Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, et al. (2010) A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 66: 181-189. doi:10.1007/s00280-010-1289-x. PubMed: 20217089.
    • (2010) Cancer Chemother Pharmacol , vol.66 , pp. 181-189
    • Rathkopf, D.1    Wong, B.Y.2    Ross, R.W.3    Anand, A.4    Tanaka, E.5
  • 10
    • 78649632254 scopus 로고    scopus 로고
    • Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer
    • doi: 10.1016/j.canlet.2010.09.013
    • Wang L, Chen H, Liu FH, Madigan MC, Power CA, et al. (2011) Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. Cancer Lett 300: 122-133. doi:10.1016/j.canlet.2010.09.013. PubMed: 21075513.
    • (2011) Cancer Lett , vol.300 , pp. 122-133
    • Wang, L.1    Chen, H.2    Liu, F.H.3    Madigan, M.C.4    Power, C.A.5
  • 11
    • 68149138779 scopus 로고    scopus 로고
    • Coexpression of invasive markers (uPA, CD44) and multiple drug resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression
    • doi: 10.1038/sj.bjc.6605185
    • Chen H, Hao J, Wang L, Li Y, (2009) Coexpression of invasive markers (uPA, CD44) and multiple drug resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101: 432-440. doi:10.1038/sj.bjc.6605185. PubMed: 19603017.
    • (2009) Br J Cancer , vol.101 , pp. 432-440
    • Chen, H.1    Hao, J.2    Wang, L.3    Li, Y.4
  • 12
    • 85047699075 scopus 로고    scopus 로고
    • In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen
    • doi: 10.1038/sj.pcan.4500543
    • Li Y, Tian Z, Rizvi SM, Bander NH, Allen BJ, (2002) In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis 5: 36-46. doi:10.1038/sj.pcan.4500543. PubMed: 15195129.
    • (2002) Prostate Cancer Prostatic Dis , vol.5 , pp. 36-46
    • Li, Y.1    Tian, Z.2    Rizvi, S.M.3    Bander, N.H.4    Allen, B.J.5
  • 13
    • 77957234813 scopus 로고    scopus 로고
    • Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression
    • doi: 10.1038/sj.bjc.6605839
    • Hao J, Chen H, Madigan MC, Cozzi PJ, Beretov J, et al. (2010) Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer 103: 1008-1018. doi:10.1038/sj.bjc.6605839. PubMed: 20736947.
    • (2010) Br J Cancer , vol.103 , pp. 1008-1018
    • Hao, J.1    Chen, H.2    Madigan, M.C.3    Cozzi, P.J.4    Beretov, J.5
  • 14
    • 79955625505 scopus 로고    scopus 로고
    • Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells
    • doi: 10.1016/j.ijrobp.2010.12.051
    • Wouters A, Pauwels B, Lambrechts HA, Pattyn GG, Ides J, et al. (2011) Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells. Int J Radiat Oncol Biol Phys 80: 558-566. doi:10.1016/j.ijrobp.2010.12.051. PubMed: 21377279.
    • (2011) Int J Radiat Oncol Biol Phys , vol.80 , pp. 558-566
    • Wouters, A.1    Pauwels, B.2    Lambrechts, H.A.3    Pattyn, G.G.4    Ides, J.5
  • 15
    • 33748360764 scopus 로고    scopus 로고
    • Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci
    • doi: 10.1158/1535-7163.MCT-06-0022
    • Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, et al. (2006) Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 5: 1967-1974. doi:10.1158/1535-7163.MCT-06-0022. PubMed: 16928817.
    • (2006) Mol Cancer Ther , vol.5 , pp. 1967-1974
    • Munshi, A.1    Tanaka, T.2    Hobbs, M.L.3    Tucker, S.L.4    Richon, V.M.5
  • 16
    • 0142186650 scopus 로고    scopus 로고
    • How low is the α/β ratio for prostate cancer?
    • doi: 10.1016/S0360-3016(03)01455-X
    • Kal HB, Van Gellekom MP, (2003) How low is the α/β ratio for prostate cancer? Int J Radiat Oncol Biol Phys 57: 1116-1121. doi:10.1016/S0360-3016(03)01455-X. PubMed: 14575844.
    • (2003) Int J Radiat Oncol Biol Phys , vol.57 , pp. 1116-1121
    • Kal, H.B.1    Van Gellekom, M.P.2
  • 17
    • 3042661957 scopus 로고    scopus 로고
    • Role of cell cycle in mediating sensitivity to radiotherapy
    • doi: 10.1016/j.ijrobp.2004.03.005
    • Pawlik TM, Keyomarsi K, (2004) Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59: 928-942. doi:10.1016/j.ijrobp.2004.03.005. PubMed: 15234026.
    • (2004) Int J Radiat Oncol Biol Phys , vol.59 , pp. 928-942
    • Pawlik, T.M.1    Keyomarsi, K.2
  • 18
    • 79954488451 scopus 로고    scopus 로고
    • Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis
    • doi: 10.1158/1541-7786.MCR-10-0471
    • Chen X, Wong JY, Wong P, Radany EH, (2011) Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Mol Cancer Res 9: 448-461. doi:10.1158/1541-7786.MCR-10-0471. PubMed: 21303901.
    • (2011) Mol Cancer Res , vol.9 , pp. 448-461
    • Chen, X.1    Wong, J.Y.2    Wong, P.3    Radany, E.H.4
  • 19
    • 84864882225 scopus 로고    scopus 로고
    • Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer
    • doi: 10.1038/bjc.2012.321
    • Kozakai N, Kikuchi E, Hasegawa M, Suzuki E, Ide H, et al. (2012) Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer. Br J Cancer 107: 652-657. doi:10.1038/bjc.2012.321. PubMed: 22805327.
    • (2012) Br J Cancer , vol.107 , pp. 652-657
    • Kozakai, N.1    Kikuchi, E.2    Hasegawa, M.3    Suzuki, E.4    Ide, H.5
  • 20
    • 0035895622 scopus 로고    scopus 로고
    • Pathways governing G1/S transition and their response to DNA damage
    • doi: 10.1016/S0014-5793(01)02114-7
    • Bartek J, Lukas J, (2001) Pathways governing G1/S transition and their response to DNA damage. FEBS Lett; 490: 117-122. doi:10.1016/S0014-5793(01)02114-7. PubMed: 11223026.
    • (2001) FEBS Lett , vol.490 , pp. 117-122
    • Bartek, J.1    Lukas, J.2
  • 21
    • 0030827303 scopus 로고    scopus 로고
    • Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein
    • doi: 10.1101/gad.11.16.2090
    • Funk JO, Waga S, Harry JB, Espling E, Stillman B, et al. (1997) Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 11: 2090-2100. doi:10.1101/gad.11.16.2090. PubMed: 9284048.
    • (1997) Genes Dev , vol.11 , pp. 2090-2100
    • Funk, J.O.1    Waga, S.2    Harry, J.B.3    Espling, E.4    Stillman, B.5
  • 22
    • 51649092237 scopus 로고    scopus 로고
    • P53, cyclin-dependent kinase and abnormal amplification of centrosomes
    • 18472015
    • Fukasawa K, (2008) P53, cyclin-dependent kinase and abnormal amplification of centrosomes. Biochim Biophys Acta 1786: 15-23. PubMed: 18472015.
    • (2008) Biochim Biophys Acta , vol.1786 , pp. 15-23
    • Fukasawa, K.1
  • 23
    • 0036261707 scopus 로고    scopus 로고
    • Sensing and repairing DNA double-strand breaks
    • doi: 10.1093/carcin/23.5.687
    • Jackson SP, (2002) Sensing and repairing DNA double-strand breaks. Carcinogenesis 23: 687-696. doi:10.1093/carcin/23.5.687. PubMed: 12016139.
    • (2002) Carcinogenesis , vol.23 , pp. 687-696
    • Jackson, S.P.1
  • 24
    • 39449085063 scopus 로고    scopus 로고
    • DNA-damage repair; the good, the bad, and the ugly
    • doi: 10.1038/emboj.2008.15
    • Hakem R, (2008) DNA-damage repair; the good, the bad, and the ugly. EMBO J 27: 589-605. doi:10.1038/emboj.2008.15. PubMed: 18285820.
    • (2008) EMBO J , vol.27 , pp. 589-605
    • Hakem, R.1
  • 25
    • 34548564426 scopus 로고    scopus 로고
    • Attenuated DNA damage repair by trichostatin A through BRCA1 suppression
    • doi: 10.1667/RR0811.1
    • Zhang Y, Carr T, Dimtchev A, Zaer N, Dritschilo A, et al. (2007) Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res 168: 115-124. doi:10.1667/RR0811.1. PubMed: 17722998.
    • (2007) Radiat Res , vol.168 , pp. 115-124
    • Zhang, Y.1    Carr, T.2    Dimtchev, A.3    Zaer, N.4    Dritschilo, A.5
  • 26
    • 84866550710 scopus 로고    scopus 로고
    • Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy
    • 22462686
    • Ahmad M, Hamid A, Hussain A, Majeed R, Qurishi Y, et al. (2012) Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy. DNA Cell Biol Suppl 1: S62-S71. PubMed: 22462686.
    • (2012) DNA Cell Biol Suppl , vol.1
    • Ahmad, M.1    Hamid, A.2    Hussain, A.3    Majeed, R.4    Qurishi, Y.5
  • 27
    • 43249120953 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis
    • doi: 10.1007/978-1-4020-6554-5_13
    • Shankar S, Srivastava RK, (2008) Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 615: 261-298. doi:10.1007/978-1-4020-6554-5_13. PubMed: 18437899.
    • (2008) Adv Exp Med Biol , vol.615 , pp. 261-298
    • Shankar, S.1    Srivastava, R.K.2
  • 28
    • 79955678223 scopus 로고    scopus 로고
    • Developing histone deacetylase inhibitors as anti-cancer therapeutics
    • doi: 10.2174/092986711795471284
    • Venugopal B, Evans TR, (2011) Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 18: 1658-1671. doi:10.2174/092986711795471284. PubMed: 21428881.
    • (2011) Curr Med Chem , vol.18 , pp. 1658-1671
    • Venugopal, B.1    Evans, T.R.2
  • 29
    • 84875839227 scopus 로고    scopus 로고
    • The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers
    • doi: 10.1111/j.1464-410X.2012.11647.x
    • Sharma NL, Groselj B, Hamdy FC, Kiltie AE, (2013) The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers. BJU Int 111(4):: 537-542. doi:10.1111/j.1464-410X.2012.11647.x. PubMed: 23551441.
    • (2013) BJU Int , vol.111 , pp. 537-542
    • Sharma, N.L.1    Groselj, B.2    Hamdy, F.C.3    Kiltie, A.E.4
  • 30
    • 84875223519 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair
    • doi: 10.1038/bjc.2013.21
    • Groselj B, Sharma NL, Hamdy FC, Kerr M, Kiltie AE, (2013) Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer 108(4):: 748-754. doi:10.1038/bjc.2013.21. PubMed: 23361058.
    • (2013) Br J Cancer , vol.108 , pp. 748-754
    • Groselj, B.1    Sharma, N.L.2    Hamdy, F.C.3    Kerr, M.4    Kiltie, A.E.5
  • 31
    • 84873823667 scopus 로고    scopus 로고
    • Epigenetics and persistent memory: implications for reconsolidation and silent extinction beyond the zero
    • doi: 10.1038/nn.3302
    • Lattal KM, Wood MA, (2013) Epigenetics and persistent memory: implications for reconsolidation and silent extinction beyond the zero. Nat Neurosci 16: 124-129. doi:10.1038/nn.3302. PubMed: 23354385.
    • (2013) Nat Neurosci , vol.16 , pp. 124-129
    • Lattal, K.M.1    Wood, M.A.2
  • 32
    • 0035142893 scopus 로고    scopus 로고
    • Chromosome regions enriched in hyperacetylated histone H4 are preferred sites for endonuclease- and radiation-induced breakpoints
    • doi: 10.1023/A:1026747801728
    • Martínez-López W, Folle GA, Obe G, Jeppesen P, (2001) Chromosome regions enriched in hyperacetylated histone H4 are preferred sites for endonuclease- and radiation-induced breakpoints. Chromosome Res 9: 69-75. doi:10.1023/A:1026747801728. PubMed: 11272794.
    • (2001) Chromosome Res , vol.9 , pp. 69-75
    • Martínez-López, W.1    Folle, G.A.2    Obe, G.3    Jeppesen, P.4
  • 33
    • 4344688693 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors
    • doi: 10.1016/S0065-230X(04)91004-4
    • Marks PA, Richon VM, Miller T, Kelly WK, (2004) Histone deacetylase inhibitors. Adv Cancer Res 91: 137-168. doi:10.1016/S0065-230X(04)91004-4. PubMed: 15327890.
    • (2004) Adv Cancer Res , vol.91 , pp. 137-168
    • Marks, P.A.1    Richon, V.M.2    Miller, T.3    Kelly, W.K.4
  • 34
    • 34250171437 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: signalling towards p21cip1/waf1
    • doi: 10.1016/j.biocel.2007.03.001
    • Ocker M, Schneider-Stock R, (2007) Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 39: 1367-1374. doi:10.1016/j.biocel.2007.03.001. PubMed: 17412634.
    • (2007) Int J Biochem Cell Biol , vol.39 , pp. 1367-1374
    • Ocker, M.1    Schneider-Stock, R.2
  • 35
    • 33748451151 scopus 로고    scopus 로고
    • Anticancer activities of histone deacetylase inhibitors
    • doi: 10.1038/nrd2133
    • Bolden JE, Peart MJ, Johnstone RW, (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784. doi:10.1038/nrd2133. PubMed: 16955068.
    • (2006) Nat Rev Drug Discov , vol.5 , pp. 769-784
    • Bolden, J.E.1    Peart, M.J.2    Johnstone, R.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.